NewsBenzingaargenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 Benzinga 2026.10.19 12:07 (GMT+0) Open on Benzinga Other news BTIG Reiterates Buy on Nexxen International, Maintains $13 Price Target Morgan Stanley Maintains Equal-Weight on Xcel Energy, Raises Price Target to $85 Morgan Stanley Maintains Equal-Weight on Western Midstream, Lowers Price Target to $52 Morgan Stanley Maintains Overweight on Vistra, Lowers Price Target to $226 Alaska Air Gr Q3 2026 Earnings Call Transcript If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
